Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
PaperCitations, authors & open-access status
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 191 citations, 2022 year and hybrid oa status.
191
Citations
2022
Year
hybrid
OA Status